Three years into the mass adoption of GLP-1 drugs for weight management, researchers now have substantially more real-world data than when prescriptions first spiked. The headline: average weight loss and cardiovascular benefits match or exceed the clinical trial results that made the drugs famous.
But the picture is more nuanced than the marketing suggests. Weight regain after discontinuation is common, lean muscle loss is a documented concern, and side-effect tolerance varies significantly across patients. Physicians increasingly emphasize that these are long-term tools, not short-term solutions.
Access remains uneven — insurance coverage and pricing differ dramatically by country, and India's market for authorized versions has only just begun to develop.
If you're considering these drugs, work with a physician who understands both the benefits and the long-term commitment they represent.